Charles M Richardson
Overview
Explore the profile of Charles M Richardson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kelly D, Glassman M, Wonodi I, Vyas G, Richardson C, Nwulia E, et al.
Schizophr Res
. 2023 Aug;
268():312-322.
PMID: 37633776
Introduction: Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, but it is markedly underutilized, particularly in the US Black population, partly because of concern over clozapine-associated low absolute neutrophil...
2.
Cavaliere V, Glassman M, DiPaula B, Mackowick M, Wehring H, Liu F, et al.
Schizophr Res
. 2022 Mar;
243:163-169.
PMID: 35358857
Introduction: Patients with severe mental illness are falsely characterized as aggressive by the media, perpetuating stigma. While exaggerated, some patients with severe mental illness are more aggressive without treatment. Clozapine...
3.
Kelly D, Kane M, Fraser C, Sayer M, Grant-Beurmann S, Liu T, et al.
J Clin Psychopharmacol
. 2021 Feb;
41(2):200-202.
PMID: 33587401
No abstract available.
4.
Friendshuh C, Pocivavsek A, Demyonovich H, Rodriguez K, cihakova D, Talor M, et al.
J Clin Psychopharmacol
. 2020 Apr;
40(3):317-319.
PMID: 32332475
No abstract available.
5.
Kelly D, Demyanovich H, Rodriguez K, cihakova D, Talor M, McMahon R, et al.
J Psychiatry Neurosci
. 2019 Apr;
44(4):269-276.
PMID: 30938127
Background: Approximately one-third of people with schizophrenia have elevated levels of anti-gliadin antibodies of the immunoglobulin G type (AGA IgG) — a higher rate than seen in healthy controls. We...
6.
Kelly D, Powell M, Wehring H, Sayer M, Kearns A, Hackman A, et al.
J Clin Psychopharmacol
. 2018 Jun;
38(4):317-326.
PMID: 29912799
Purpose/background: Prolactin-related adverse effects contribute to nonadherence and adverse health consequences, particularly in women with severe mental illness. Treating these adverse effects may improve treatment acceptability, adherence, and long-term outcomes....
7.
Patchan K, Vyas G, Hackman A, Mackowick M, Richardson C, Love R, et al.
Psychiatr Q
. 2017 Jun;
89(1):157-168.
PMID: 28643049
Popular media often portray people with a mental illness as being aggressive, violent, and incarcerated as a result of their behavior. Despite exaggeration in the media, risks for some aggressive...
8.
Wehring H, Elsobky T, McEvoy J, Vyas G, Richardson C, McMahon R, et al.
Psychiatr Q
. 2017 May;
89(1):73-80.
PMID: 28466366
Clozapine is the sole antipsychotic agent effective for the treatment of refractory schizophrenia. Sixty percent of clozapine-treated patients, however, fail to adequately respond. Minocycline, a tetracycline antibiotic, possesses antiinflammatory and...
9.
Richardson C, Davis E, Vyas G, DiPaula B, McMahon R, Kelly D
J Clin Psychiatry
. 2016 Oct;
77(11):e1454-e1459.
PMID: 27736047
Objective: To determine if clozapine can be safely utilized in psychiatric patients with benign neutropenia. Methods: A single-center, retrospective chart review study of records from 2001 to 2014 was conducted...
10.
Kelly D, Sullivan K, McEvoy J, McMahon R, Wehring H, Gold J, et al.
J Clin Psychopharmacol
. 2015 Jun;
35(4):374-81.
PMID: 26082974
Objective: Clozapine is the most effective antipsychotic for treatment refractory people with schizophrenia, yet many patients only partially respond. Accumulating preclinical and clinical data suggest benefits with minocycline. We tested...